DAS181 for Severe COVID-19: Compassionate Use
Overview
The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 16, 2020
Detailed Description
Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the first day of administration. From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml) nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg (3.5m1) DAS181 should be delivered with about 12-hour interval.
Interventions
- Drug: DAS181
- Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Arms, Groups and Cohorts
- Experimental: DAS181 Treatment
- Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days
Clinical Trial Outcome Measures
Primary Measures
- Improved clinical status
- Time Frame: Day 14
- Percent of subjects with improved clinical status
- Return to room air
- Time Frame: Day 14
- Percent of subjects return to room air
Secondary Measures
- SARS-CoV-2 RNA
- Time Frame: 28 days
- time to SARS-CoV-2 RNA in the respiratory specimens being undetectable
- Discharge
- Time Frame: Days 14, 21, 28
- Percent of patients discharge from hospital
- Death
- Time Frame: Day 14, 21, 28
- All-cause mortality rate
Participating in This Clinical Trial
Key Inclusion Criteria:
1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens 2. Hypoxemic 3. Severe COVID-19 4. If female, subject must not be pregnant or nursing. 5. Non-vasectomized males are required to practice effective birth control methods 6. Capable of understanding and complying with procedures as outlined in the protocol as judged by the Investigator and able to sign informed consent form prior to the initiation of any screening or study-specific procedures. Exclusion Criteria:
1. ALT or AST> 8 x ULN 2. (ALT or AST> 3 x ULN) and (Total bilirubin> 2.5 x ULN or INR> 2.0 x ULN) 3. Female subjects who have a positive pregnancy test and are breastfeeding 4. Subjects using any other investigational antiviral drugs during the hospitalization before enrollment. 5. Subjects participating in other clinical trials 6. Subjects may be transferred to a non-participating hospital within 72 hours 7. People who cannot cooperate well due to mental illness, have no self-control, and cannot express clearly 8. Severe underlying diseases affecting survival 9. Critical COVID-19 requiring mechanical ventilator at the time enrolled
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Collaborator
- Ansun Biopharma, Inc.
- Provider of Information About this Clinical Study
- Principal Investigator: Gong Zuojiong, Director, Department of Infectious Disease – Renmin Hospital of Wuhan University
- Overall Official(s)
- Zuojiong Gong, MD, Principal Investigator, Renmin Hospital of Wuhan University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.